Phase III Trial to Study Combination of Genentech’s Actemra, Gilead’s Remdesivir vs. Severe COVID-19

Genentech, a member of the Roche Group, said its marketed arthritis drug Actemra®(tocilizumab) will be studied with Gilead Sciences’ antiviral candidate remdesivir as a combination treatment for hospitalized patients with severe COVID-19, through a Phase III clinical trial the companies have launched.

Read the full article here

Related Articles